The estimated Net Worth of Charles Theuer is at least $1.16 Миллион dollars as of 26 April 2023. Charles Theuer owns over 50,999 units of TRACON Pharmaceuticals Inc stock worth over $27,560 and over the last 10 years he sold TCON stock worth over $43,392. In addition, he makes $1,085,320 as President, Chief Executive Officer и Director at TRACON Pharmaceuticals Inc.
Charles has made over 41 trades of the TRACON Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 50,999 units of TCON stock worth $37,739 on 26 April 2023.
The largest trade he's ever made was buying 50,999 units of TRACON Pharmaceuticals Inc stock on 26 April 2023 worth over $37,739. On average, Charles trades about 7,455 units every 44 days since 2015. As of 26 April 2023 he still owns at least 399,417 units of TRACON Pharmaceuticals Inc stock.
You can see the complete history of Charles Theuer stock trades at the bottom of the page.
DR. Charles P. Theuer M.D., Ph.D. serves as President, Chief Executive Officer, Director of the Company. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016, and also serves as a director at Oncternal Therapeutics, Inc., a position he has held since 2018.
As the President, Chief Executive Officer и Director of TRACON Pharmaceuticals Inc, the total compensation of Charles Theuer at TRACON Pharmaceuticals Inc is $1,085,320. There are no executives at TRACON Pharmaceuticals Inc getting paid more.
Charles Theuer is 56, he's been the President, Chief Executive Officer и Director of TRACON Pharmaceuticals Inc since 2019. There are 8 older and 6 younger executives at TRACON Pharmaceuticals Inc. The oldest executive at TRACON Pharmaceuticals Inc is William LaRue, 69, who is the Independent Director.
Charles's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.
Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell и Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include: